ProfoundBio secures $112m to advance ADC portfolio for cancer
ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.
Eric Dobmeier News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eric Dobmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eric Dobmeier Today - Breaking & Trending Today
ProfoundBio Raises $112M in Series B Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SEATTLE, July 28, 2023 -- Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today...
Source: marketscreener.com
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives $35.83 Consensus PT from Brokerages
Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Free Report) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […]
Source: modernreaders.com
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Short Interest Update
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,130,000 shares, an increase of 72.0% from the June 15th total of 1,820,000 shares. Based on an average daily volume of 1,410,000 shares, […]
Source: wkrb13.com